nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—Raised liver function tests—Teniposide—lymphatic system cancer	0.0372	0.0372	CcSEcCtD
Ezogabine—Urinary hesitation—Fludarabine—lymphatic system cancer	0.0368	0.0368	CcSEcCtD
Ezogabine—Chromaturia—Mitoxantrone—lymphatic system cancer	0.0251	0.0251	CcSEcCtD
Ezogabine—Myoclonus—Vincristine—lymphatic system cancer	0.0153	0.0153	CcSEcCtD
Ezogabine—Encephalopathy—Carmustine—lymphatic system cancer	0.015	0.015	CcSEcCtD
Ezogabine—Aphasia—Carmustine—lymphatic system cancer	0.0149	0.0149	CcSEcCtD
Ezogabine—Hypokinesia—Carmustine—lymphatic system cancer	0.0143	0.0143	CcSEcCtD
Ezogabine—Coma—Fludarabine—lymphatic system cancer	0.0138	0.0138	CcSEcCtD
Ezogabine—Nystagmus—Vincristine—lymphatic system cancer	0.0129	0.0129	CcSEcCtD
Ezogabine—Liver function test abnormal—Teniposide—lymphatic system cancer	0.0115	0.0115	CcSEcCtD
Ezogabine—Alopecia—Mechlorethamine—lymphatic system cancer	0.0103	0.0103	CcSEcCtD
Ezogabine—Liver function test abnormal—Fludarabine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Ezogabine—Neutropenia—Teniposide—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Ezogabine—Gait disturbance—Carmustine—lymphatic system cancer	0.00989	0.00989	CcSEcCtD
Ezogabine—Coordination abnormal—Carmustine—lymphatic system cancer	0.00983	0.00983	CcSEcCtD
Ezogabine—Raised liver function tests—Methotrexate—lymphatic system cancer	0.00968	0.00968	CcSEcCtD
Ezogabine—Dysphagia—Fludarabine—lymphatic system cancer	0.00946	0.00946	CcSEcCtD
Ezogabine—Gait disturbance—Vincristine—lymphatic system cancer	0.00944	0.00944	CcSEcCtD
Ezogabine—Vertigo—Mechlorethamine—lymphatic system cancer	0.00914	0.00914	CcSEcCtD
Ezogabine—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00911	0.00911	CcSEcCtD
Ezogabine—Disorientation—Bleomycin—lymphatic system cancer	0.00897	0.00897	CcSEcCtD
Ezogabine—Neutropenia—Fludarabine—lymphatic system cancer	0.00885	0.00885	CcSEcCtD
Ezogabine—Dysuria—Fludarabine—lymphatic system cancer	0.00885	0.00885	CcSEcCtD
Ezogabine—Coma—Carmustine—lymphatic system cancer	0.00882	0.00882	CcSEcCtD
Ezogabine—Coma—Vincristine—lymphatic system cancer	0.00842	0.00842	CcSEcCtD
Ezogabine—Infection—Mechlorethamine—lymphatic system cancer	0.00825	0.00825	CcSEcCtD
Ezogabine—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00813	0.00813	CcSEcCtD
Ezogabine—Haematuria—Fludarabine—lymphatic system cancer	0.00804	0.00804	CcSEcCtD
Ezogabine—Alopecia—Teniposide—lymphatic system cancer	0.00761	0.00761	CcSEcCtD
Ezogabine—Amnesia—Carmustine—lymphatic system cancer	0.00746	0.00746	CcSEcCtD
Ezogabine—Visual impairment—Fludarabine—lymphatic system cancer	0.0073	0.0073	CcSEcCtD
Ezogabine—Diplopia—Carmustine—lymphatic system cancer	0.00701	0.00701	CcSEcCtD
Ezogabine—Encephalopathy—Methotrexate—lymphatic system cancer	0.00696	0.00696	CcSEcCtD
Ezogabine—Aphasia—Methotrexate—lymphatic system cancer	0.00689	0.00689	CcSEcCtD
Ezogabine—Leukopenia—Teniposide—lymphatic system cancer	0.00671	0.00671	CcSEcCtD
Ezogabine—Alopecia—Fludarabine—lymphatic system cancer	0.00669	0.00669	CcSEcCtD
Ezogabine—Malnutrition—Fludarabine—lymphatic system cancer	0.00659	0.00659	CcSEcCtD
Ezogabine—Liver function test abnormal—Carmustine—lymphatic system cancer	0.00647	0.00647	CcSEcCtD
Ezogabine—Urinary retention—Vincristine—lymphatic system cancer	0.00636	0.00636	CcSEcCtD
Ezogabine—Confusional state—Teniposide—lymphatic system cancer	0.00617	0.00617	CcSEcCtD
Ezogabine—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Ezogabine—Infection—Teniposide—lymphatic system cancer	0.00608	0.00608	CcSEcCtD
Ezogabine—Dysphagia—Carmustine—lymphatic system cancer	0.00605	0.00605	CcSEcCtD
Ezogabine—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00599	0.00599	CcSEcCtD
Ezogabine—Malaise—Fludarabine—lymphatic system cancer	0.00594	0.00594	CcSEcCtD
Ezogabine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00592	0.00592	CcSEcCtD
Ezogabine—Leukopenia—Fludarabine—lymphatic system cancer	0.0059	0.0059	CcSEcCtD
Ezogabine—Haematuria—Bleomycin—lymphatic system cancer	0.0059	0.0059	CcSEcCtD
Ezogabine—Neutropenia—Carmustine—lymphatic system cancer	0.00566	0.00566	CcSEcCtD
Ezogabine—Discomfort—Fludarabine—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Ezogabine—Dyspnoea—Teniposide—lymphatic system cancer	0.00546	0.00546	CcSEcCtD
Ezogabine—Confusional state—Fludarabine—lymphatic system cancer	0.00542	0.00542	CcSEcCtD
Ezogabine—Dysuria—Vincristine—lymphatic system cancer	0.0054	0.0054	CcSEcCtD
Ezogabine—Neutropenia—Vincristine—lymphatic system cancer	0.0054	0.0054	CcSEcCtD
Ezogabine—Infection—Fludarabine—lymphatic system cancer	0.00534	0.00534	CcSEcCtD
Ezogabine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00528	0.00528	CcSEcCtD
Ezogabine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00527	0.00527	CcSEcCtD
Ezogabine—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00526	0.00526	CcSEcCtD
Ezogabine—Rash—Mechlorethamine—lymphatic system cancer	0.00524	0.00524	CcSEcCtD
Ezogabine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00523	0.00523	CcSEcCtD
Ezogabine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.0052	0.0052	CcSEcCtD
Ezogabine—Weight increased—Mitoxantrone—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Ezogabine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00504	0.00504	CcSEcCtD
Ezogabine—Skin discolouration—Methotrexate—lymphatic system cancer	0.00495	0.00495	CcSEcCtD
Ezogabine—Nausea—Mechlorethamine—lymphatic system cancer	0.00493	0.00493	CcSEcCtD
Ezogabine—Alopecia—Bleomycin—lymphatic system cancer	0.00491	0.00491	CcSEcCtD
Ezogabine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Ezogabine—Hallucination—Carmustine—lymphatic system cancer	0.00482	0.00482	CcSEcCtD
Ezogabine—Dyspnoea—Fludarabine—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Ezogabine—Haematuria—Mitoxantrone—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Ezogabine—Oedema peripheral—Carmustine—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Ezogabine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00474	0.00474	CcSEcCtD
Ezogabine—Dysarthria—Methotrexate—lymphatic system cancer	0.00473	0.00473	CcSEcCtD
Ezogabine—Visual impairment—Carmustine—lymphatic system cancer	0.00467	0.00467	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Ezogabine—Fatigue—Fludarabine—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Ezogabine—Hallucination—Vincristine—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Ezogabine—Constipation—Fludarabine—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Ezogabine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Ezogabine—Urethral disorder—Vincristine—lymphatic system cancer	0.00453	0.00453	CcSEcCtD
Ezogabine—Eye disorder—Carmustine—lymphatic system cancer	0.00453	0.00453	CcSEcCtD
Ezogabine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Ezogabine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Ezogabine—Asthenia—Teniposide—lymphatic system cancer	0.00439	0.00439	CcSEcCtD
Ezogabine—Malaise—Bleomycin—lymphatic system cancer	0.00436	0.00436	CcSEcCtD
Ezogabine—Leukopenia—Bleomycin—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Ezogabine—Alopecia—Carmustine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Ezogabine—Mental disorder—Carmustine—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Ezogabine—Malnutrition—Carmustine—lymphatic system cancer	0.00422	0.00422	CcSEcCtD
Ezogabine—Alopecia—Vincristine—lymphatic system cancer	0.00409	0.00409	CcSEcCtD
Ezogabine—Coma—Methotrexate—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Ezogabine—Discomfort—Bleomycin—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Ezogabine—Mental disorder—Vincristine—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Ezogabine—Alopecia—Mitoxantrone—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Ezogabine—Confusional state—Bleomycin—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Ezogabine—Vision blurred—Carmustine—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Ezogabine—Tremor—Carmustine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Ezogabine—Infection—Bleomycin—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Ezogabine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Ezogabine—Asthenia—Fludarabine—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Ezogabine—Rash—Teniposide—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Ezogabine—Dermatitis—Teniposide—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Ezogabine—Leukopenia—Carmustine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Ezogabine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Ezogabine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Ezogabine—Nausea—Teniposide—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Ezogabine—Vertigo—Vincristine—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Ezogabine—Leukopenia—Vincristine—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Ezogabine—Anxiety—Carmustine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Ezogabine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Ezogabine—Malaise—Mitoxantrone—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Ezogabine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Ezogabine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Ezogabine—Confusional state—Carmustine—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Ezogabine—Infection—Carmustine—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Ezogabine—Rash—Fludarabine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Ezogabine—Dermatitis—Fludarabine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Ezogabine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Ezogabine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Ezogabine—Discomfort—Mitoxantrone—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Ezogabine—Infection—Vincristine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Ezogabine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Ezogabine—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Ezogabine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Ezogabine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Ezogabine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Ezogabine—Nausea—Fludarabine—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Ezogabine—Infection—Mitoxantrone—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Ezogabine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Ezogabine—Shock—Mitoxantrone—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Ezogabine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Ezogabine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Ezogabine—Paraesthesia—Carmustine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Ezogabine—Dyspnoea—Carmustine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Ezogabine—Somnolence—Carmustine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Ezogabine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.003	0.003	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Ezogabine—Paraesthesia—Vincristine—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Ezogabine—Constipation—Carmustine—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Ezogabine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Ezogabine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Ezogabine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Ezogabine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Ezogabine—Fatigue—Vincristine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Ezogabine—Asthenia—Bleomycin—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Ezogabine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Ezogabine—Constipation—Vincristine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Ezogabine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Ezogabine—Constipation—Mitoxantrone—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Ezogabine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Ezogabine—Neutropenia—Methotrexate—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Ezogabine—Dysuria—Methotrexate—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Ezogabine—Infestation NOS—Methotrexate—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Ezogabine—Infestation—Methotrexate—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Ezogabine—Rash—Bleomycin—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Ezogabine—Dermatitis—Bleomycin—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Ezogabine—Asthenia—Carmustine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Ezogabine—Haematuria—Methotrexate—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Ezogabine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Ezogabine—Asthenia—Vincristine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Ezogabine—Nausea—Bleomycin—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Ezogabine—Asthenia—Mitoxantrone—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Ezogabine—Dizziness—Carmustine—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Ezogabine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Ezogabine—Urethral disorder—Methotrexate—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Ezogabine—Dizziness—Vincristine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Ezogabine—Rash—Carmustine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Ezogabine—Dermatitis—Carmustine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Ezogabine—Visual impairment—Methotrexate—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Ezogabine—Eye disorder—Methotrexate—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Ezogabine—Rash—Vincristine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Ezogabine—Dermatitis—Vincristine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Ezogabine—Nausea—Carmustine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Ezogabine—Rash—Mitoxantrone—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Ezogabine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Ezogabine—Alopecia—Methotrexate—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Ezogabine—Mental disorder—Methotrexate—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Ezogabine—Malnutrition—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Ezogabine—Nausea—Vincristine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Ezogabine—Nausea—Mitoxantrone—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Ezogabine—Vision blurred—Methotrexate—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Ezogabine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Ezogabine—Malaise—Methotrexate—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Ezogabine—Vertigo—Methotrexate—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Ezogabine—Leukopenia—Methotrexate—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Ezogabine—Discomfort—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Ezogabine—Confusional state—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Ezogabine—Infection—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Ezogabine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Ezogabine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Ezogabine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Ezogabine—Paraesthesia—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Ezogabine—Dyspnoea—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Ezogabine—Somnolence—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Ezogabine—Dyspepsia—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Ezogabine—Fatigue—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Ezogabine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Ezogabine—Asthenia—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Ezogabine—Dizziness—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Ezogabine—Rash—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Ezogabine—Dermatitis—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Ezogabine—Nausea—Methotrexate—lymphatic system cancer	0.000947	0.000947	CcSEcCtD
